BIIB max pain for the Nov 27, 2026 expiry is $252.50, from the Fri Nov 20 options chain. The last price, $249.59, is 1.2% below it. Call wall $252.50 · put floor $247.50.
What the institutional money is doing on BIIB right now — dark pool, options positioning, and where the news and the money disagree. Free.
The money right now
Dark pool share
31.1% (market avg 49%)
Dark pool volume vs its norm
0.9×
Short share of that
68.4% (norm 60%)
Max pain
$252.50
Nov 27 exp
Call wall
$252.50
Nov 27 exp
Put floor
$247.50
Nov 27 exp
Dark pool share: 31% off-exchange — 18pp below the market
Off-exchange prints never touch the public book, so they move size without moving the quote. That is the point of using them. Most of the day cleared on the lit market — either there was nothing to hide, or the large players sat out. Short share of the off-exchange piece: 68% vs a 60% norm.
Source: FINRA · Fri 11/20 close
What it means: On Fri 11/20 close, BIIB's off-exchange volume was 0.89x its 20-day average, with 68.4% of that volume short versus its 60% norm, while traded options favored calls over puts. This is mixed positioning: call-heavy options flow contrasts with off-exchange selling pressure, and the 11/27 Call Wall at $252.5 sits above the $249.59 price. Watch whether it closes below the 11/27 Put Floor at $247.5.
News vs the money
Why Biogen's shares keep rising despite market turmoil
The bullish headline partly aligns with call-heavy options trading, but off-exchange volume was below its norm and its short share was above its own norm on Fri 11/20, a mixed signal rather than clear institutional accumulation.
Seeking Alpha · 11/20
Biogen downgraded as growth and Alzheimer's progress are seen in the price
The cautious valuation view conflicts with call-heavy options trading, while Fri 11/20 off-exchange short activity was above its own norm, leaving the overall signal mixed.
Seeking Alpha · 11/19
Study reports favorable lecanemab results in a subgroup with Alzheimer's
The positive study news has some support from call-heavy options trading, but Fri 11/20 off-exchange volume was below its norm and its short share was elevated versus its own norm, so the signals are mixed.
PRNewsWire · 11/19
Biogen readies lupus trial results as it seeks renewed revenue growth
The growth-focused news partly aligns with call-heavy options trading, but Fri 11/20 off-exchange short activity was above its own norm and volume was below its norm, making positioning mixed.
Defense World · 11/19
Bogart Wealth increased its Biogen stake in the third quarter
The reported purchase is consistent with call-heavy options trading, but Fri 11/20 off-exchange activity showed below-normal volume and an above-normal short share, so the wider money signals are mixed.
Defense World · 11/19
What is a “divergence”?
A divergence is when the news narrative and the institutional money flow point in opposite directions — a bearish headline while large call premium is bought, or heavy dark-pool selling under a bullish story. It signals the crowd and the desks may disagree.
How to read these numbers
Dark-pool volume — The share of trading executed off-exchange, at wholesalers and dark pools. About half of all US share volume prints there on an ordinary day, so the level by itself says almost nothing. What carries information is the distance from this name’s own recent norm, and whether the off-exchange size ran above its usual.
Off-exchange short share — How much of that off-exchange volume was sold short. The median across all listed names is about 49%, because wholesalers filling retail buy orders sell short and cover later. A reading near half is plumbing, not a bearish vote — compare it to the same name’s own 20-day norm.
Max pain — The price where the most options expire worthless — positioning often gravitates toward it near expiry.
Call wall / Put floor — Strikes with the heaviest call/put open interest — they often act as short-term resistance and support.
Put/Call ratio — Below ~0.7 leans bullish (more calls); above ~1 leans defensive (more puts).